The impact of patent expiry on drug prices: insights from the Dutch market.

Autor: van der Schans S; Unit of Global Health, Department of Health Sciences, University Medical Centre Groningen, Groningen, The Netherlands.; Fair Medicine Foundation, Amsterdam, The Netherlands., Vondeling GT; Department of Global Market Access & Pricing, Daiichi Sankyo, München, Germany., Cao Q; Unit of Global Health, Department of Health Sciences, University Medical Centre Groningen, Groningen, The Netherlands.; Unit of PharmacoTherapy, -epidemiology & -economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands., van der Pol S; Unit of Global Health, Department of Health Sciences, University Medical Centre Groningen, Groningen, The Netherlands., Visser S; Data Scientia, Groningen, The Netherlands., Postma MJ; Unit of Global Health, Department of Health Sciences, University Medical Centre Groningen, Groningen, The Netherlands.; Unit of PharmacoTherapy, -epidemiology & -economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands.; Department of Economics, Econometrics & Finance, University of Groningen, Faculty of Economics & Business, Groningen, The Netherlands., Rozenbaum MH; Department of Patient & Health Impact, Pfizer, Inc, Capelle A/d IJssel, The Netherlands.
Jazyk: angličtina
Zdroj: Journal of market access & health policy [J Mark Access Health Policy] 2020 Dec 01; Vol. 9 (1), pp. 1849984. Date of Electronic Publication: 2020 Dec 01.
DOI: 10.1080/20016689.2020.1849984
Abstrakt: Background : Currently literature on the impact of patent expiry on drug prices is lacking. Objective : To determine the impact of patent expiration and generic entry on drug prices in the Netherlands. Methods : Prescription and price data from 1999 up to and including December 2016 were collected from two national databases. The overall price ratio of drugs prices up to 48 months after patent expiration was compared to the price in the month before expiry. Sub-analyses were performed to provide insights in generic uptake, length of market exclusivity and price development for originators and generics separately. Results : In total 250 drugs faced patent expiration during the study period. Forty-eight months after patent expiration the median price ratio decreased to 0.59 (IQR = 0.23-0.86) compared to the month prior patent expiry. Major differences in price developments were observed depending on the level of revenue prior to patent expiration and the time of patent expiration with ratios ranging from 0.08 (IQR = 0.07-0.16) to 0.81 (IQR = 0.62-0.97). Prior to patent expiry, the price decreased by 2.3% annually while having market exclusivity for 11.3 years on average. Conclusion : This study showed that the median drug price after patent expiration decreased by 41% after 4 years. The results of this study can be used to provide more reliable estimates on drug prices over its lifecycle and can be implemented in economic evaluations to inform the cost-effectiveness and long-term budget impact of new drugs.
(© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje